13F HOLDINGS REPORT
REGENERON PHARMACEUTICALS, INC.
Quarter ended Q3 2025 · Filed November 7, 2025 · Accession 0001104659-25-108546
Total Value
$700.4M
Positions
4
Other Managers
0
Confidential Omitted
No
Holdings (4)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Alnylam Pharmaceuticals, Inc. | ALNY | 1,392,303 | $634.9M | 90.64% |
| 2 | Intellia Therapeutics, Inc. | NTLA | 3,702,995 | $64.0M | 9.13% |
| 3 | Adverum Biotechnologies, Inc. | 00773U207 | 180,909 | $819,518 | 0.12% |
| 4 | Adicet Bio, Inc. | ACET | 968,183 | $784,422 | 0.11% |